Literature DB >> 31478401

An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.

Marena R Niewisch1, Sharon A Savage1.   

Abstract

Introduction: Telomere biology disorders (TBDs) encompass a group of illnesses caused by germline mutations in genes regulating telomere maintenance, resulting in very short telomeres. Possible TBD manifestations range from complex multisystem disorders with onset in childhood such as dyskeratosis congenita (DC), Hoyeraal-Hreidarsson syndrome, Revesz syndrome and Coats plus to adults presenting with one or two DC-related features.Areas covered: The discovery of multiple genetic causes and inheritance patterns has led to the recognition of a spectrum of clinical features affecting multiple organ systems. Patients with DC and associated TBDs are at high risk of bone marrow failure, cancer, liver and pulmonary disease. Recently, vascular diseases, including pulmonary arteriovenous malformations and gastrointestinal telangiectasias, have been recognized as additional manifestations. Diagnostics include detection of very short leukocyte telomeres and germline genetic testing. Hematopoietic cell transplantation and lung transplantation are the only current therapeutic modalities but are complicated by numerous comorbidities. This review summarizes the pathophysiology underlying TBDs, associated clinical features, management recommendations and therapeutic options.Expert opinion: Understanding TBDs as complex, multisystem disorders with a heterogenous genetic background and diverse phenotypes, highlights the importance of clinical surveillance and the urgent need to develop new therapeutic strategies to improve health outcomes.

Entities:  

Keywords:  Coats plus; Hoyeraal-Hreidarsson syndrome; Revesz syndrome; Telomere; bone marrow failure; cancer; dyskeratosis congenita; pulmonary fibrosis; telomere biology disorder

Mesh:

Year:  2019        PMID: 31478401      PMCID: PMC9400112          DOI: 10.1080/17474086.2019.1662720

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.819


  188 in total

1.  Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation.

Authors:  Tom J Vulliamy; Anna Marrone; Stuart W Knight; Amanda Walne; Philip J Mason; Inderjeet Dokal
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

2.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

Authors:  Mohamad M Al-Rahawan; Neelam Giri; Blanche P Alter
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  CTC1 Mutations in a patient with dyskeratosis congenita.

Authors:  Rachel B Keller; Katelyn E Gagne; G Naheed Usmani; George K Asdourian; David A Williams; Inga Hofmann; Suneet Agarwal
Journal:  Pediatr Blood Cancer       Date:  2012-04-24       Impact factor: 3.167

4.  Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

Authors:  Banu A Karimi-Shah; Badrul A Chowdhury
Journal:  N Engl J Med       Date:  2015-03-26       Impact factor: 91.245

Review 5.  Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.

Authors:  Andrew C Dietz; Sharon A Savage; Adrianna Vlachos; Parinda A Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

Review 6.  Survival after Hematopoietic Stem Cell Transplant in Patients with Dyskeratosis Congenita: Systematic Review of the Literature.

Authors:  Pasquale Barbaro; Aditi Vedi
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

7.  Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.

Authors:  Raphael Borie; Laure Tabèze; Gabriel Thabut; Hilario Nunes; Vincent Cottin; Sylvain Marchand-Adam; Grégoire Prevot; Abdellatif Tazi; Jacques Cadranel; Herve Mal; Lidwine Wemeau-Stervinou; Anne Bergeron Lafaurie; Dominique Israel-Biet; Clement Picard; Martine Reynaud Gaubert; Stephane Jouneau; Jean-Marc Naccache; Julie Mankikian; Christelle Ménard; Jean-François Cordier; Dominique Valeyre; Marion Reocreux; Bernard Grandchamp; Patrick Revy; Caroline Kannengiesser; Bruno Crestani
Journal:  Eur Respir J       Date:  2016-11-11       Impact factor: 16.671

Review 8.  A regulatory loop connecting WNT signaling and telomere capping: possible therapeutic implications for dyskeratosis congenita.

Authors:  Rafael Jesus Fernandez; F Brad Johnson
Journal:  Ann N Y Acad Sci       Date:  2018-04       Impact factor: 5.691

9.  Human RTEL1 deficiency causes Hoyeraal-Hreidarsson syndrome with short telomeres and genome instability.

Authors:  Tangui Le Guen; Laurent Jullien; Fabien Touzot; Michael Schertzer; Laetitia Gaillard; Mylène Perderiset; Wassila Carpentier; Patrick Nitschke; Capucine Picard; Gérard Couillault; Jean Soulier; Alain Fischer; Isabelle Callebaut; Nada Jabado; Arturo Londono-Vallejo; Jean-Pierre de Villartay; Patrick Revy
Journal:  Hum Mol Genet       Date:  2013-04-15       Impact factor: 6.150

10.  Cerebroretinal microangiopathy with calcifications and cysts (CRMCC).

Authors:  T A Briggs; G M H Abdel-Salam; M Balicki; P Baxter; E Bertini; N Bishop; B H Browne; D Chitayat; W K Chong; M M Eid; W Halliday; I Hughes; A Klusmann-Koy; M Kurian; K K Nischal; G I Rice; J B P Stephenson; R Surtees; J F Talbot; N N Tehrani; J L Tolmie; C Toomes; M S van der Knaap; Y J Crow
Journal:  Am J Med Genet A       Date:  2008-01-15       Impact factor: 2.802

View more
  41 in total

Review 1.  Extrahematopoietic manifestations of the short telomere syndromes.

Authors:  Kristen E Schratz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Telomere length in hematopoietic cell transplant.

Authors:  Shahinaz M Gadalla
Journal:  Blood       Date:  2020-12-24       Impact factor: 22.113

3.  A novel homozygous RTEL1 variant in a consanguineous Lebanese family: phenotypic heterogeneity and disease anticipation.

Authors:  Fernanda Gutierrez-Rodrigues; Nohad Masri; Eliane Chouery; Carrie Diamond; Nadine Jalkh; Alana Vicente; Sachiko Kajigaya; Fayez Abillama; Noha Bejjani; Wassim Serhal; Rodrigo T Calado; Neal S Young; Hussein Farhat; Marie Louise Coussa
Journal:  Hum Genet       Date:  2019-11-01       Impact factor: 4.132

4.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

5.  Small Molecules Restore Telomeres in Patient Stem Cells.

Authors:  Kirsten Ann Brenner; Jayakrishnan Nandakumar
Journal:  Trends Pharmacol Sci       Date:  2020-05-29       Impact factor: 14.819

6.  Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Authors:  Joseph H Oved; Daria V Babushok; Michele P Lambert; Nicole Wolfset; M Anna Kowalska; Mortimer Poncz; Konrad J Karczewski; Timothy S Olson
Journal:  Blood Adv       Date:  2020-10-27

7.  A Case of Presumed Dyskeratosis Congenita Causing Severe Retinal Vascular Occlusion.

Authors:  Takahisa Hirokawa; Shou Oosuka; Masahiro Tonari; Hiroshi Mizuno; Teruyo Kida; Akiko Inoue; Akira Ashida; Tsunehiko Ikeda
Journal:  Case Rep Ophthalmol       Date:  2021-05-07

8.  RTEL1 influences the abundance and localization of TERRA RNA.

Authors:  Fiorella Ghisays; Aitor Garzia; Hexiao Wang; Claudia Canasto-Chibuque; Marcel Hohl; Sharon A Savage; Thomas Tuschl; John H J Petrini
Journal:  Nat Commun       Date:  2021-05-21       Impact factor: 14.919

9.  Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene.

Authors:  Z Belaya; O Golounina; A Nikitin; N Tarbaeva; E Pigarova; E Mamedova; M Vorontsova; I Shafieva; I Demina; W Van Hul
Journal:  Osteoporos Int       Date:  2020-11-27       Impact factor: 4.507

Review 10.  Telomerase RNA processing: Implications for human health and disease.

Authors:  Neha Nagpal; Suneet Agarwal
Journal:  Stem Cells       Date:  2020-09-01       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.